ARTICLE | Company News
Ligand, Tap Pharmaceutical deal
July 19, 2004 7:00 AM UTC
LGND received a $1 million milestone from TAP under a 2001 deal to develop selective androgen receptor modulators (SARMs) to treat various diseases, including osteoporosis and sexual dysfunction (see...